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ABSTRACT
Introduction: While the current COVID-19
pandemic has affected the lives of many, there
is a paucity of information on the impact on
people with multiple sclerosis (MS). This study
sought to gain insight into the impact of the
current situation on people with MS and the
factors that influence this.
Methods: 324 MS patients participated in this
online cross-sectional survey during the
COVID-19 lockdown period. A mixed methods
design was used, with quantitative information
collected on MS-related factors as well as
COVID-19 impact and an open-ended, qualita-
tive response looking for reasons behind the
self-reported COVID-19 impact.
Results: We found that 48% of the participants
reported that COVID-19 had a neutral impact
on their lives and 16% reported a positive
impact. However, 36% reported a negative
impact, and had greater levels of MS- and non-
MS-related worries, and higher levels of bother
related to psychological and cognitive symp-
toms and fatigue than the groups reporting a
neutral or positive impact. Significant predic-
tors of this adversely affected group were age,
type of MS and presence of psychological
symptoms. Antidepressant medication use, time
since diagnosis, gender, location, living
arrangements or employment status did not
predict impact. Open-ended responses explain-
ing personal COVID-19 impact indicate that
coping strategies may contribute to these find-
ings. In particular, active, problem-focused
approaches were reported by the majority of
people who reported a positive impact, as well
as a third of those who reported a neutral
impact.
Conclusion: These findings suggest that
younger people, those with progressive types of
MS, and those with psychological symptoms are
particularly vulnerable to the negative effects of
a COVID-19 pandemic induced lockdown.
Coping strategies provide further insight into
these findings with those reporting active
problem-focused approaches seemingly faring
better than those who do not state any coping
strategies. These results also have implications
for understanding other like neurological con-
ditions that share many similarities with MS
and how best to direct support.
H. Morris-Bankole  A. K. Ho (&)
School of Psychology and Clinical Language






People with Multiple Sclerosis (MS) are more
vulnerable to psychological disorders such as
anxiety. Consequences of the COVID-19 pan-
demic could potentially heighten these levels
due to the impact on health and healthcare. An
online survey was completed by 324 people
with MS during the COVID-19 pandemic to
identify the level of COVID-19 impact (positive,
neutral or negative) and the reasons why they
felt this way. Findings show that just under half
of people who completed the survey reported a
neutral impact, with a negative impact reported
by just over a third of participants. Having a
progressive diagnosis of MS, being younger and
having psychological symptoms predicted a
negative impact. Coping strategies also appear
to play a part in the COVID-19 experience for
people with MS, with active, problem-focused
strategies being an approach used by nearly all
who reported a positive impact and over a third
of people who reported a neutral impact. These
findings can be used to direct support to the
most vulnerable people within this population
as well as those with other neurological
conditions.
Keywords: Anxiety; Concern; Coping; COVID-
19; Low mood; Multiple sclerosis; Pandemic;
Psychological well-being
Key Summary Points
Why carry out this study?
People with MS are more vulnerable to
poor psychological well-being.
There are conflicting reports about
whether anxiety has increased or
remained the same during the COVID-19
pandemic.
What was learned from the study?
Just under half of our sample of people
with MS reported a neutral COVID-19
impact, and over a third reported a
negative impact.
Some demographic and MS-related factors
(younger age, progressive types of MS and
presence of psychological symptoms) can
predict a negative COVID-19 impact.
Both emotion-focused and problem-
focused coping strategies were
instrumental in those reporting a neutral
or positive impact from the COVID-19
pandemic.
DIGITAL FEATURES
This article is published with digital features,
including a summary slide and plain language
summary, to facilitate understanding of the arti-
cle. To view digital features for this article go to
https://doi.org/10.6084/m9.figshare.14161361
INTRODUCTION
The COVID-19 pandemic has had at least some
level of impact on everyone as restrictions have
been enforced globally. Restrictions can poten-
tially impact many aspects of life, including
finances, social and family relationships, travel,
access to healthcare and leisure activities,
amongst others. As a result, an increased level of
mental health concerns have been observed
worldwide [1].
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The prevalence of anxiety (22%) is dispro-
portionately higher in people with MS than the
general population [2]. It may therefore be
expected that heightened levels of anxiety [3]
and higher levels of MS-related concerns [4]
may be reported during the current COVID-19
pandemic, in particular worries that cause con-
cern about MS and a future living with it in the
context of COVID-19 being those that have the
strongest impact on the current pandemic
experience [5].
Other recent research, however, has arrived
at alternative conclusions, that in fact levels of
anxiety have not increased as a result of the
current crisis and have even improved in some
cases [6, 7]. These findings are surprising given
the typical psychological presentation of MS
patients, as well as the potential to exacerbate
such factors further due to the nature of the
COVID-19 pandemic and its potential impact on
MS care [8]. These studies, however, looked at
groups belonging to a particular demographic
according to a specific location or diagnostic
category, andmay suggest that other factorsmay
account for seemingly contradictory findings.
Differences in identification of vulnerable
groups determined by demographic features
have yielded varying results. Older MS patients
may be more vulnerable to the effects of social
isolation as a result of the pandemic [5]. How-
ever, research has also shown that younger
people with MS are more vulnerable to anxiety
at this time [9, 10]. Similarly, women have been
reported to be more susceptible to anxiety than
men at this time [8], yet opposite results have
also been found in other research, suggesting
men are experiencing higher levels of anxiety
during the COVID-19 pandemic [5]. This pro-
vides further evidence to suggest that there are
other factors that could be at play, such as
coping strategies.
Historically, research has suggested that
people with MS who rely on problem-focused
strategies fare better in the process of adjust-
ment compared to those who favour emotion-
focused approaches [11]. Therefore, it might be
anticipated that those who are coping with the
COVID-19 pandemic using less-effective coping
mechanisms may be more vulnerable to a neg-
ative experience and those who use problem-
focused approaches may report a positive
impact.
Aside from the underlying traits and mech-
anisms that could underpin the reasons behind
a positive, neutral or negative impact, there are
also objective factors that could contribute to
the level of impact.
Whilst having MS itself does not necessarily
increase the risk of contracting COVID-19 [12],
many people with MS are prescribed disease-
modifying treatments with immunosuppressant
effects that may make the user potentially more
vulnerable to contracting the virus [13]. On the
otherhand, it is knownthat somepeople feel that
the risks of remaining on immunosuppressant
therapies is favourable to risking disease relapse
or progression [14]. Either way, being presented
with this dilemma is an additional burden
experienced by MS patients at this time.
Access and quality of caremay also be affected
in the wake of the pandemic and local lockdown
restrictions [15] which may affect symptom
management and increase MS-related concerns
[16]. Therefore, it might be expected that those
who report higher levels of MS-related concern
and symptom bother would be more likely to
endorse a negative impact of COVID-19. Self-
perceived levels of symptom concern may then
be responsible for less-adaptive coping methods
[17]. On the other hand, it is possible that the
overall impact may be perceived as neutral as
there may be positive impacts due to the com-
plex interplay of personal, household and
external factors within the context of the pan-
demic. In particular, factors such as increased
social contact with close family members could
facilitate a positive experience [18].
With existing literature focusing on the
COVID-19 experience as a whole, none have
sought to examine the differences between
those who self-report different levels of impact,
either negative, neutral, or even positive. There
are several factors warranting further investiga-
tion that could identify who is most vulnerable
to a negative experience, both in terms of
demographics and MS status, as well as any self-
reported reasons for COVID-19 impact that may
differentiate between those who experience a
negative impact when compared to those who
experience a neutral or positive impact.
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Based on what is already known about the
experience of MS generally and the current lit-
erature on the impact of COVID-19 on people
with MS, we sought to understand the level of
impact of COVID-19 experienced by people
with MS and the factors that could be con-
tributing to this that might help to explain any
discrepancies in recent findings.
To build on what is currently known, we
took a more direct approach by asking partici-
pants a single question about the overall impact
of COVID-19 (negative, neutral or positive) to
provide an assessment of the ensuing conse-
quence on their lives. An open ended follow-up
question asking participants to provide insight
into the circumstances that led to the negative,
neutral or positive COVID-19 impact they
experienced gave participants the opportunity
to spontaneously raise relevant contributing
factors. This, along with regression data on
demographic factors identifying those who are
most vulnerable to a negative impact, could be
used to identify helpful coping strategies as
stated by the positive and possibly neutral
groups to direct and shape support to those who
are not faring so well at this time.
As these multifaceted consequences of the
pandemic and lockdown impact bothMS-related
andnon-MS-related elements of everyday life,we
expected that on balance, the impact of COVID-
19 would be largely neutral in the majority of
people withMS, with only a subset of individuals
experiencing a negative impact. We also inves-
tigated whether demographic and MS-related
variables in particular might predict those who
report a negative impact of COVID-19.
METHODS
Participants
324 people (273 females, 51males) withMS (68%
relapsing remitting, 8% primary progressive,
16% secondary progressive and 8% clinically
isolated syndrome or unsure) aged between 20
and 75 (M = 47.66, SD = 12.19) responded from
the UK (40%), USA (34%), Australia (3%) and
other countries (23%). The age range of people
with relapse-remittingMSwas 20–75 (M = 45.67,
SD = 11.82) and for progressive types of MS was
30–74 with a slightly higher average age
(M = 55.95, SD = 10.36).
The inclusion criteria for participation were a
self-reported diagnosis of MS (or responding in
behalf of someonewithMS;n = 4) andbeingover
the ageof 18. Exclusion criteriawerenodiagnosis
of MS and not being over the age of 18.
Data Collection and Measurements
An online survey on the broad topic of ‘psy-
chological support in MS’ was conducted during
the COVID-19 lockdown period, from mid-
March to mid-August, 2020. Data were collected
on the experiences of psychological support as
well as psychological variables listed below rel-
evant to the present study. Participants were
recruited via various MS organisations globally
as well as MS social media groups via
e-newsletters and/or social media posts with a
link to the online survey.
Participants were asked to provide demo-
graphic information such as age, gender, loca-
tion, employment status, type of MS and time
since diagnosis. Additionally, participants were
requested to rate on a Likert-type scale from 1 to
5 how bothered they were by broad clusters of
common MS symptoms including motor, such
as mobility issues; sensory, such as numbness
and tingling; cognitive, such as problems with
memory and attention; and psychological
symptoms, such as anxiety and depression; as
well as fatigue. As variables that could poten-
tially interact with the impact of COVID-19,
they were also investigated in this present
study. These data are presented in Table 1.
Participants were also asked to indicate their
overall self-perceived level of impact of the
current COVID-19 pandemic on them gener-
ally, including their MS (positive, such as
spending more time with family; neutral, that is
little or no impact; or negative, such as anxieties
about MS medications). They were then asked
to briefly provide some insight into why they
reported this level of impact.
As part of the broader survey, participants
were also asked to indicate their level of concern
regarding factors that are often reported to be
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impacted by a diagnosis of MS, such as anxiety,
loss, impact on relationships and life goals, on a
Likert scale of 1–3.
Data Analysis
Quantitative data were analysed using IBM
Statistical Package for the Social Sciences (SPSS)
software version 25.0. A multinomial regression
was conducted to identify which variables, if
any, could predict a negative impact of the
COVID-19 pandemic. A series of one-way
ANOVAs were performed to explore differences
in levels of MS-related concern and symptom
bother between the three different levels of
COVID-19 impact. Due to the uneven distribu-
tion between the three COVID-19 impact
groups, Welch’s F was used as a more robust
alternative. Qualitative data briefly describing
reasons for the reported level of COVID-19
impact were analysed by identifying general
themes and presented as frequencies and per-
centages. These were then compared between
the three different levels of overall COVID-19
impact (positive, neutral or negative).
Ethical Considerations
Ethical approval was obtained from the
University of Reading Ethics Committee (ap-
proval number: UREC 16/30). This study was
performed in accordance with the Helsinki












































RRMS relapsing–remitting multiple sclerosis, CIS clinically
isolated syndrome
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Declaration of 1964 and its later amendments.
Participants provided written informed consent
digitally before completing the survey.
RESULTS
COVID-19 Impact
We found that 36% (n = 117) endorsed a nega-
tive COVID-19 impact; however, 16% (n = 52)
reported a positive impact, and the most com-
mon response was a neutral impact, 48%
(n = 155). This suggests that for just under half
of the people in this sample, the overall impact
of COVID-19 has been largely neutral. Just over
a third have experienced negative consequences
of COVID-19, with the least number of people
reporting a positive impact. Despite the sample
residing in different countries, the pattern of
results was similar in the countries from where
the largest number of participants are repre-
sented (n[100; UK and USA), with most
reporting a neutral impact (42%, UK; 55%,
USA), closely followed by a negative impact
(41%, UK; 32%, USA) and the least common
impact was positive (17%, UK; 13%, USA).
Predicting COVID-19 Impact
To predict those negatively impacted by the
COVID-19 lockdown, demographic and MS-re-
lated variables were entered into a multinomial
regression.
The full model, including age, gender, loca-
tion, employment status, living arrangements,
whether taking medication for a mood disorder
or not, type of MS, years diagnosed with MS and
presence (or absence) of symptoms provides a
statistically significant improvement in fit over
a null model (v2 (30) = 74.04, p\0.001).
Age, type of MS and self-reported presence of
psychological symptoms (such as anxiety and
depression) were the significant predictors in
the model where lower age predicted increased
likelihood of reporting a negative response than
a neutral (b = 1.07, SE = 0.01, p\ 0.001) or
positive (b = 1.04, SE = 0.02, p\0.05) response.
People with progressive types of MS were more
likely to report a negative response than a pos-
itive one (b = 0.10), SE = 0.94, p\0.05), and
those who reported having psychological
symptoms in relation to their MS were also
more likely to report a negative impact than a
neutral (b = 8.02), SE = . 80, p\ 0.01) or posi-
tive impact (b = 9.11, SE = 0.90, p\0.05).
Gender, location, employment status, living
arrangements, and taking mood disorder medi-
cation were not significant predictors of level of
COVID-19 impact in the model.
Relationship Between MS Concerns
and Symptom Bother and COVID-19
Experience
When investigating levels of MS-related con-
cerns between the three different levels of
COVID-19 impact, statistically significant main
effects were observed between group means as
determined by a one-way ANOVA for all types
of MS-related concern examined (anxiety,
Welch’s F(2, 143.58 = 14.26, p\0.01; sadness,
Welch’s F(2, 141.05) = 10.73, p\ 0.01; loss,
Welch’s F(2, 141.88) = 10.49, p\0.01; coping,
Welch’s F(2, 136.52) = 12.55, p\ 0.01; uncer-
tainty, Welch’s F(2, 140.61) = 6.05, p\ 0.01;
control, Welch’s F(2, 141.26) = 4.75, p\ 0.05;
function, Welch’s F(2, 139.44) = 8.54, p\ 0.01;
disease progression, Welch’s F(2,
137.82) = 8.36, p\0.01; fatigue, Welch’s F(2,
139.12) = 7.93, p\ 0.01; lifestyle change,
Welch’s F(2, 135.92) = 8.39, p\ 0.01; life goals,
Welch’s F(2, 136.67) = 7.93, p\ 0.01; family
impact, Welch’s F(2, 140.18) = 4.42, p\ 0.05;
relationship impact, Welch’s F(2,
136.53) = 7.68, p\ 0.01.
Table 2 shows the means for each concern
variable at each level of COVID-19 impact. In all
cases, the mean level of concern for each vari-
able was significantly higher amongst those
who reported a negative impact compared to
those who reported a neutral and/or positive
impact. Three patterns of response were evi-
dent. First, the negative group had significantly
higher concerns (about anxiety, sadness, loss,
coping, fatigue, lifestyle change, life goal
impact and relationship impact) than both the
neutral and positive groups, which were similar.
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Second, both the negative and neutral groups
had significantly higher concern (about ability
to function) than the positive group. Third, the
negative and positive groups both showed sta-
tistically higher levels of concern (about
uncertainty, control, disease progression and
family impact) than the neutral group.
To examine differences in level of symptom
bother experienced between the different levels
of COVID-19 impact (see Table 2), a further
series of one-way ANOVAs were conducted.
Results indicate no significant differences
between the level of bother experienced by
sensory and motor symptoms between each
level of COVID-19 impact. However, statisti-
cally significant differences were observed for
levels of current bother for fatigue (Welch’s
F(2,131.40) = 7.27, p\0.01), psychological
symptoms (Welch’s F(2,136.60) = 11.69,
p\0.01) and cognitive symptoms (Welch’s
F(2,146.75) = 4.31, p\ 0.05).
As illustrated in Table 2, the means for each
symptom bother variable between each level of
COVID-19 impact was higher in the negative
impact group. For psychological symptoms and
fatigue, this was significantly higher than both
neutral and positive impact groups, and for
Table 2 Means of MS related concern ratings (1–3) and symptom bother (1–5) for each level of COVID-19 impact (where
a higher number indicates a higher rated level of concern)
Negative Neutral Positive
Concern ratings
Feelings of anxiety 2.38 [ 1.92 = 1.98
Feeling low/sad 2.33 [ 1.93 = 2.00
Feelings of loss 2.31 [ 1.91 = 2.00
Lack of resources to cope 2.21 [ 1.75 = 1.77
Uncertainty about the future 2.51 [ 2.23 \ 2.35
Lack of control of my MS 2.42 [ 2.15 \ 2.31
Ability to function as I want 2.62 = 2.39 [ 2.21
Worry about MS disease progression 2.57 [ 2.28 \ 2.44
Fatigue 2.69 [ 2.38 = 2.40
Having to make lifestyle changes 2.38 [ 2.08 = 2.00
Impact on my life goals 2.52 [ 2.21 = 2.21
Worry about impact on my family 2.48 [ 2.23 \ 2.35
Impact on relationships with others 2.45 [ 2.17 = 2.10
Symptom bother
Motor symptoms 2.90 = 2.67 = 2.29
Sensory symptoms 3.51 = 3.17 = 3.13
Cognitive symptoms 2.949 = 2.57 = 2.23
Psychological symptoms 3.44 [ 2.67 = 2.56
Fatigue 3.91 [ 3.35 = 3.08
Symbols between ratings depict direction of statistical significance (p\ 0.05).
X Significant difference between negative and positive (p\ 0.05)
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cognitive symptoms the mean was significantly
higher than the positive group alone.
The COVID-19 Pandemic Experience
for MS Patients
Figure 1 illustrates a breakdown of the broad
themes identified as given in the responses
provided by participants in the open-ended
question, as well as the types of responses that
were included in each theme in brackets.
All participants who reported a negative
impact (n = 117) stated some form of health-
related concern for themselves or others. In
particular, concerns like facing uncertainty,
reduced immune function and worsening
symptoms (n = 76, 65%) and interruptions to
treatment in terms of medication and/or con-
tact with medical professionals (n = 44, 38%)
were the top contributors to a negative COVID-
19 impact.
Regarding those who reported a neutral
impact, a large percentage of people stated no
change (n = 89, 57%) either due to still being
able to work, or because they already felt iso-
lated. Like those who reported a negative
Fig. 1 Frequency of reasons stated for overall level of COVID-19 impact
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impact, heightened levels of concern in relation
to fear for self and others, treatment interrup-
tion, isolation and non-MS related worries fea-
tured in 42% (n = 65) of this group. However,
unlike the negative impact group, there was also
evidence to suggest that certain coping strate-
gies were instrumental in neutralising the
impact of some of the negative consequences of
the COVID-19 pandemic. Both problem-fo-
cused (n = 59, 38%) and emotion-focused
approaches (n = 23, 15%) were utilised by this
group to this effect. For example, acceptance: ‘I
am anxious about Covid 19 but that is set-
tling… I am doing the sensible thing and am
now accepting 2020 is the year that never was’
and positive reframing: ‘My anxiety levels are
high from risk of becoming ill…Working from
home has had a hugely positive impact on my
well-being and my stamina to walk has
increased to a great level—am healthier than
I’ve been in a long time and stress is definitely
reduced’ are amongst the emotion-focused
strategies used by this group in response to any
negative impact experienced.
Like the neutral group, 15% of the positive
group also reported using emotion-focused
strategies. However, the dominating coping
approach used by this group was the use of
problem-focused strategies (88%, n = 46). Active
problem-focused strategies were used the most
frequently by making use of the additional time
gained as a result of the lockdown to be with
family (n = 27, 52%): ‘I’m not the easiest person
to be around because of my MS so in isolation
with my family allows me time to mend
bridges’, actively choosing to engage in self-care
by slowing the pace down and resting (n = 14,
27%): ‘I am currently working from home
which has allowed me more time and flexibility
to look after myself, including my diet, exercise
regimes and stress management‘, or engaging in
existing or new hobbies (n = 11, 21%): ‘I started
doing yoga and prepared more meals at home’.
DISCUSSION
This study adds further understanding to the
experience of the COVID-19 pandemic in MS
patients by highlighting which factors
contribute to this experience. By further
exploring the net effect of COVID-19 conse-
quences on individuals and factors most
prevalent in each impact group (negative, neu-
tral or positive) we provide a more detailed
insight into the experience amongst MS
patients.
Overall, our hypothesis was supported with
the most common experience being neutral, as
reported by just under half of our sample. This
was closely followed by over a third of partici-
pants who reported a negative impact; they had
greater levels of MS-related concerns and MS
symptom bother from psychological, cognitive
and fatigue symptoms. Demographic variables
that predicted this negative impact were
younger age, progressive types of MS and the
presence of psychological symptoms. This is
consistent with previous research [9, 10] that
found those of a younger age to be more vul-
nerable to the negative effects of COVID-19 in
the form of increased anxiety at this time.
However, the present study also found that
location, gender, employment status, time since
diagnosis and mood disorder medication use
were not significant predictors of negative
impact in the model which provides some evi-
dence to the contrary that gender, in this case,
has no relationship with the self-reported
impact of COVID-19 [5, 8].
It was also found that MS-related concerns
(such as feelings of loss, impact on relationships
and disease progression) and bother related to
psychological and cognitive symptoms and
fatigue were higher amongst those who repor-
ted a negative impact. In this case, it may be
that since these were MS-specific outcomes, it
naturally matched the concerns that might be
had amidst the COVID-19 pandemic and
therefore might be expected that higher levels
of these factors related to a negative pandemic
experience. In the case of symptom bother, this
would also lend support to previous studies that
have identified MS care being impacted at this
time [15].
On the other hand, it may seem surprising to
find that levels of bother related to motor
symptoms were statistically similar between the
three impact groups despite it being found that
people with progressive types of MS, typically
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characterised by motor difficulties, were more
likely to report a negative impact. However, this
could possibly be explained by examining cop-
ing approaches as expressed in the open-ended
responses. For example, an interesting finding
reflecting this is noted when examining con-
cern about disease progression. In this case,
scores were statistically similar between those
who rated a negative and positive COVID-19
impact, but higher than those who rated a
neutral impact, indicating a higher level of
concern for disease progression amongst both
those who reported negative and positive
COVID-19 impacts compared to those who
reported a neutral impact. When taking into
account the open-ended responses in the neu-
tral category, it would appear that coping
strategies exhibited by those in the neutral cat-
egory could be responsible for the neutralising
effect. In this way, a potentially negative impact
could be reduced to something more manage-
able and therefore yielding a neutral effect. This
particular example provides insight into how
coping strategies may be responsible for differ-
ent experiences explained by demographic fac-
tors, MS related concerns and symptom bother
between the impact groups.
Furthermore, heightened levels of health-re-
lated concern were qualitatively identified as
the most common experience regardless of
what level of COVID-19 impact was reported.
This provides further support to previous claims
suggesting heightened levels of anxiety are
being experienced in people with MS during the
COVID-19 pandemic [5]. Further qualitative
outcomes in the present study also provide
insight into factors that may contribute to
understanding why other studies have found
evidence to the contrary, that anxiety levels
have not increased at this time [5, 7]. People
who reported a neutral impact, despite com-
monly reporting health-related concerns, also
reported the use of both problem- and emotion-
focused coping strategies that seemingly neu-
tralised the negative effects of COVID-19. This
points towards coping as a mechanism that may
be a factor that contributes to previous dis-
crepancies in findings.
Additionally, the present study presents evi-
dence that active, problem-focused coping
strategies are utilised more frequently by those
who report a positive impact and by some who
report a neutral impact. This supports previous
claims that active coping strategies could be
related to more positive outcomes [11], and in
this case, a positive or neutral COVID-19
impact. These coping methods are largely
absent amongst those who reported a negative
impact. This finding in particular may provide
insight into any discrepancies that have been
found in recent research between whether
anxieties are increasing for people with MS or
not at this time [5, 6]. This may also be an
indication that, for some people with MS who
are well accustomed to dealing with uncertain-
ties and limitations that arise as a result of their
illness, they are already equipped with skills to
cope effectively with yet another situation that
stimulates feelings of uncertainty.
Dividing COVID-19 impact into three dis-
tinct categories—negative, neutral and posi-
tive—has allowed for a more detailed
examination into factors that play a significant
role in the negative experience of the COVID-19
pandemic, whilst taking into account self-re-
ported overall impact and using this as a basis to
compare experiences at this time. The direct
approach taken allowed us to understand the
overall perceived COVID-19 impact in people
with MS as well as the relevant contributing
factors. However, the costs of taking this
approach arguably led to some potential chal-
lenges. For example, the use of self-report
meant that information such as type of MS
could not be clinically verified. The oppor-
tunistic nature of type of sample itself may be
responsible for some level of bias in terms of
how and from where participants were recruited
in this global sample. Three-point Likert scales
were considered appropriate for the nature of
this study, but may arguably result in limited
granularity. Similarly, a single question to assess
overall impact was the most suitable way of
allowing participants to self-assess all factors
relevant to them individually and reflect this in
a single overall response. Participants were free
to provide information on any factors that were
meaningful in making their choice of overall
impact; however, more systematic scrutiny of a
range of specific factors such as exposure to
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COVID-19 and level of disability was outside
the scope of the current study.
This study was strengthened by the strong
sample size and has shown that the detrimental
impact of COVID-19 can be predicted by a
progressive diagnosis of MS, being younger and
having psychological symptoms. Furthermore,
our novel and direct approach allowed partici-
pants to explore the factors that contributed to
their experience based on what is most mean-
ingful to them. This insightful qualitative data
allowed us to generate a model of pandemic
impact in MS patients (see Fig. 2) that may also
be applicable to other chronic neurological
conditions with similar characteristics.
Our summary model in Fig. 2 identifies key
risk factors, stressors and coping strategies that
determine the perceived impact of a pandemic
and its repercussions on everyday life. In par-
ticular, it highlights the types of coping strate-
gies utilised that could be applied in a practical
way to encourage support those in the more
vulnerable sub-group to promote a more posi-
tive or at least neutral impact. Given the nature
of chronic illness more generally, such approa-
ches are also likely to be useful for targeting
support in similar neurological conditions.
CONCLUSIONS
These findings suggest that younger patients,
those with a progressive diagnosis and those
with psychological symptoms, such as anxiety
and depression, are particularly vulnerable to
the negative effects of a COVID-19-induced
lockdown, and may therefore benefit from fur-
ther support. With the rapidly evolving nature
of healthcare delivery, alternatives to face-to-
face modes of support may be helpful to ame-
liorate the negative pandemic-induced reper-
cussions on daily life and well-being. Coping
strategies appear to be related to the overall
COVID-19 impact experienced, with active,
problem-focused approaches featuring most
frequently amongst the positive and neutral
impact groups, with evidence of some emotion-
focused approaches being used by these groups
as well. The practical strategies summarised in
Fig. 2 have been helpful in our sample. Taken
together, our data serve as a pragmatic well-be-
ing guide, as well as a timely call to action for
more MS support in a post COVID-19 world,
particularly in those whom we have identified
as being most vulnerable.
Fig. 2 Summary model of COVID-19 impact in MS patients
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